Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276)

63.78+0.18+0.28%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- JPMorgan Boosts Stake in Hengrui Pharma (01276) by Approximately 1.13 Million Shares at HK$74.61 Per Share
  Stock News · 01-09 20:03
  JPMorgan Boosts Stake in Hengrui Pharma (01276) by Approximately 1.13 Million Shares at HK$74.61 Per Share
- ZhTong AH Statistics | January 9th
  Stock News · 01-09 16:22
  ZhTong AH Statistics | January 9th
- China's Biopharma Sector Enters New Year On A high
  Benzinga_recent_news · 01-08 19:02
  China's Biopharma Sector Enters New Year On A high
- Hengrui Pharmaceuticals Wins China Marketing Approval for Gastric Cancer Drug
  MT Newswires Live · 01-08 11:36
  Hengrui Pharmaceuticals Wins China Marketing Approval for Gastric Cancer Drug
- BRIEF-Jiangsu Hengrui Pharmaceuticals Says Unit Got Notice From NMPA For Retlirafusp Alfa Injection
  Reuters · 01-07
  BRIEF-Jiangsu Hengrui Pharmaceuticals Says Unit Got Notice From NMPA For Retlirafusp Alfa Injection
- Jiangsu Hengrui Pharmaceuticals - Unit Got Notice From Nmpa China for Retlirafusp Alfa Injection
  THOMSON REUTERS · 01-07
  Jiangsu Hengrui Pharmaceuticals - Unit Got Notice From Nmpa China for Retlirafusp Alfa Injection
- Suzhou Suncadia Biopharmaceuticals Wins NMPA Drug Approval
  Reuters · 01-07
  Suzhou Suncadia Biopharmaceuticals Wins NMPA Drug Approval
- HENGRUI PHARMA (01276) Cumulatively Repurchased 8.8987 Million A-Shares by End of December
  Stock News · 01-04
  HENGRUI PHARMA (01276) Cumulatively Repurchased 8.8987 Million A-Shares by End of December
- Zhiton AH Statistics | January 2nd
  Stock News · 01-02
  Zhiton AH Statistics | January 2nd
- Hong Kong Stocks Movement | Hengrui Pharma (01276) Surges Over 5% in Afternoon Session as CLDN18.2 ADC Gastric Cancer Indication Included in Breakthrough Therapy List
  Stock News · 01-02
  Hong Kong Stocks Movement | Hengrui Pharma (01276) Surges Over 5% in Afternoon Session as CLDN18.2 ADC Gastric Cancer Indication Included in Breakthrough Therapy List
- Jiangsu Hengrui Medicine Co. Ltd. Held Extraordinary Shareholders' Meeting
  Reuters · 2025-12-31
  Jiangsu Hengrui Medicine Co. Ltd. Held Extraordinary Shareholders' Meeting
- Zhixintong Hong Kong Stock Short Position Statistics | December 29
  Stock News · 2025-12-29
  Zhixintong Hong Kong Stock Short Position Statistics | December 29
- HENGRUI PHARMA (600276.SH) Signs Exclusive Licensing Agreement with HANSOH PHARMA for SHR6508 Project
  Stock News · 2025-12-28
  HENGRUI PHARMA (600276.SH) Signs Exclusive Licensing Agreement with HANSOH PHARMA for SHR6508 Project
- Hengrui Pharma to Release 2025 Annual Report on March 26, 2026; Q4 Consensus Revenue Forecasted at 32.07-36.06 Billion Yuan
  Deep News · 2025-12-26
  Hengrui Pharma to Release 2025 Annual Report on March 26, 2026; Q4 Consensus Revenue Forecasted at 32.07-36.06 Billion Yuan
- Zhiton AH Statistics | December 26
  Stock News · 2025-12-26
  Zhiton AH Statistics | December 26
- Jiangsu Hengrui Pharmaceuticals (600276.SH): Injectable SHR-A1904 Included in Breakthrough Therapy List
  Stock News · 2025-12-24
  Jiangsu Hengrui Pharmaceuticals (600276.SH): Injectable SHR-A1904 Included in Breakthrough Therapy List
- BRIEF-JPMorgan& Co's Long Position In H-Shares Of Jiangsu Hengrui Pharmaceuticals Increases To 8.29%, HKEX Says
  Reuters · 2025-12-15
  BRIEF-JPMorgan& Co's Long Position In H-Shares Of Jiangsu Hengrui Pharmaceuticals Increases To 8.29%, HKEX Says
- JPMorgan Increases Stake in Hengrui Pharma (01276) by 3.88 Million Shares at HK$72.60 per Share
  Stock News · 2025-12-15
  JPMorgan Increases Stake in Hengrui Pharma (01276) by 3.88 Million Shares at HK$72.60 per Share
- JPMorgan Chase & Co's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 8.29% on Dec 9 From 6.79% - HKEX
  THOMSON REUTERS · 2025-12-15
  JPMorgan Chase & Co's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 8.29% on Dec 9 From 6.79% - HKEX
- HENGRUI PHARMA's Ovarian Cancer Drug Fuzuloparib (FZOCUS-1 Study) Published in Top Oncology Journal "CA"
  Deep News · 2025-12-15
  HENGRUI PHARMA's Ovarian Cancer Drug Fuzuloparib (FZOCUS-1 Study) Published in Top Oncology Journal "CA"
Company Profile
Company Name
江苏恒瑞医药股份有限公司
Industry
医药制造业
Listing Date
2000-10-18
Registered Capital
663719万元
Introduction
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇胺片、碘佛醇注射液。

1D
5D
Day
Week
Month

Loading ...

High

64.20

Open

63.58

T/O Rate

0.67%

Low

62.80

63.60

Amplitude

2.20%

To The Moon

Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276)

Company Profile

Most Discussed